KoVax
Vaccines for Viral and Bacterial Diseases in Fish
Company Overview
Snapshot
Founded in March 2003 by Orit Kotler, KoVax operated with 1–10 employees. The company was acquired by Phibro Animal Health in December 2018, marking a significant exit in the aquaculture vaccine sector.
Business overview
KoVax specializes in the development and manufacturing of aquaculture vaccines designed to combat viral and bacterial diseases in fish. The company also offers diagnostic services across all stages of fish growth. Its core technology includes producing and marketing autogenous vaccines for bacterial diseases, notably the patented CyHV3 (KHV) vaccine and KV3 for koi and common carp, which KoVax acquired from the Hebrew University and the Israeli Ministry of Agriculture. KoVax has also developed a vaccine against TLV (TiLV), serving the aquaculture, veterinary, and agtech sectors.
Strategic signal
In December 2018, KoVax was acquired by Phibro Animal Health, a global animal health firm. This acquisition positioned KoVax to become part of a larger innovation powerhouse in the aquaculture vaccine market, signaling a strategic consolidation within the industry aimed at expanding reach and accelerating vaccine development for fish diseases.
Log in to access full profile ›Company Intelligence Q&A
- When was KoVax founded and by whom?
- KoVax was founded in March 2003 by Orit Kotler.
- What was a significant corporate milestone for KoVax?
- KoVax was acquired by Phibro Animal Health in December 2018, leading to its current inactive status.
- What type of products does KoVax offer?
- KoVax develops and manufactures aquaculture vaccines for viral and bacterial diseases in fish, including patented vaccines like CyHV3 (KHV) and KV3, and a vaccine against TLV (TiLV).
- What was the strategic impact of the acquisition by Phibro Animal Health?
- The acquisition by Phibro Animal Health in December 2018 was intended to create a vaccine innovation powerhouse, integrating KoVax's specialized aquaculture vaccine technology into a broader animal health portfolio.
- What intellectual property does KoVax hold in its vaccine portfolio?
- KoVax holds patents for vaccines such as CyHV3 (KHV) and KV3 for koi and common carp, which were acquired from the Hebrew University and the Israeli Ministry of Agriculture.